Dr. Min Li is Chief Scientist of Huahai Pharmaceutical, Co. and Board Chair of Shanghai Synergy Pharmaceutical Sciences (SSPS). He received PhD from Johns Hopkins University in 1991. Following a postdoctoral research in medicinal chemistry, he worked for several multinational pharmaceutical companies with increasing responsibilities, including Roche, Merck. Schering-Plough, and Merck again. Over the years, he has led technical teams of senior-level scientists for various analytical and pharmaceutical manufacturing process investigations and troubleshooting, impurity research and qualification, study of drug degradation chemistry, analytical development, and support for new drug filing. In 2014, he joined Huahai Pharmaceutical, a leading Chinese pharmaceutical company with operations in both China and US, as Vice President for Analytical Operation. He also established the Center of Excellence for Modern Analytical Technologies (CEMAT), a technical core group created for solving the most challenging technical problems from pharmaceutical R&D to scale-up and production at the company. Between June 2020 and May 2023, Dr. Li was also responsible for Huahai’s small molecule innovative drug research and development in the capacity of General Manager of SSPS, a subsidiary of Huahai. During the three year tenure, his team successfully filed two INDs and established two candidates for pre-clinical studies.